DSRLF.US DiaSorin S.p.A

Healthcare Biotechnology USA Stocks
92.00 USD
Close of Nov 14, 2026
63.61 92.00
Market cap
USD 4.53B
P/E
29.0x
P/B
2.85x
ROE
17.1%
Dividend yield
1.64%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is DSRLF.US undervalued?

Graham number
Price92.00
Graham value47.98
Premium91.8%

DSRLF.US trades 91.8% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

DiaSorin S.p.A fundamental analysis

No fundamental analysis for DiaSorin S.p.A yet.

DiaSorin S.p.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About DiaSorin S.p.A

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV…

Full company profile